Androgenetic alopecia — male pattern baldness — affects approximately 50% of men by age 50 and 85% by age 70. Those statistics are unremarkable in clinical circles. What is remarkable is how much revenue the cosmetic industry generates from this condition: the global hair loss treatment market exceeded $9 billion in 2025, the vast majority of which is captured by products that have never demonstrated clinical efficacy in peer-reviewed trials. Biotin gummies. DHT-blocking shampoos. Laser combs. "Hormone-free" serums. The marketing language borrows from clinical science. The evidence does not.
This article covers only treatments supported by peer-reviewed clinical data. Everything else — regardless of how compelling the before/after photography or how prominent the dermatologist endorsement — is outside scope. If a treatment does not have at minimum one well-designed randomised controlled trial demonstrating statistically significant outcomes, it does not appear here. That is the filter. Use it yourself when evaluating anything this article does not mention.
The Biology of Male Pattern Hair Loss
Dihydrotestosterone — DHT — is the androgen primarily responsible for male pattern hair loss. It is not testosterone itself. DHT is converted from testosterone by the enzyme 5-alpha reductase (5-AR), which exists in two isoforms: Type I (found predominantly in skin, liver and scalp) and Type II (found in hair follicles and the prostate). This distinction matters because therapeutic interventions target different points in this conversion pathway.
Once produced, DHT binds to androgen receptors in hair follicles. The critical variable is genetic predisposition: some follicles — genetically determined — express a higher density of androgen receptors and greater sensitivity to DHT. When DHT binds to these receptors, it initiates follicle miniaturisation: the anagen (active growth) phase of the hair cycle progressively shortens across successive cycles. Where a healthy terminal hair follicle might sustain an anagen phase of 3–5 years, a miniaturising follicle may reduce this to months. Simultaneously, the telogen (resting) phase lengthens. The resulting hair fibre produced at each cycle becomes finer, shorter and less pigmented — a process called vellus transformation — until the follicle eventually produces no terminal hair at all.
Pattern progression is classified by the Norwood Scale, which runs from Type I (minimal recession) to Type VII (only a horseshoe band of hair remaining at the sides and back). This scale is useful for communication between clinicians and patients, and as a framework for setting treatment expectations. Early-stage loss (Norwood I–III) responds better to all treatments than advanced loss (Norwood V–VII), where miniaturised follicles may be beyond pharmacological rescue.
Genetic predisposition is the primary driver of androgenetic alopecia, but it is not the only variable. Chronic stress elevates cortisol, which can disrupt the hair cycle and induce telogen effluvium (a separate condition causing diffuse shedding). Nutritional deficiencies — particularly ferritin, zinc and vitamin D — can exacerbate hair loss in genetically susceptible individuals. Thyroid dysfunction frequently presents with hair loss as a secondary symptom. These factors are worth ruling out before initiating pharmacological treatment, which is precisely why the protocol below begins with a dermatologist visit rather than a pharmacy trip.
Treatment Tier 1 — Clinically Proven
Minoxidil (Topical)
FDA-approved for male pattern hair loss since 1988, topical minoxidil has the longest safety and efficacy record of any hair loss treatment. Its discovery was accidental: minoxidil was originally developed as an oral antihypertensive in the 1970s, and patients using it orally began reporting unexpected hair growth as a side effect. Researchers investigated, and topical formulations were subsequently developed and approved.
The exact mechanism of minoxidil's hair-promoting effect remains incompletely understood despite 35+ years of use. The most well-supported hypothesis is that it acts as a vasodilator — increasing blood flow and oxygen delivery to the dermal papilla of the follicle — and as a potassium channel opener that prolongs the anagen phase. At the 5% concentration, it outperforms 2% with comparable side-effect profiles. Foam formulations have become the preferred delivery vehicle for most clinical settings: they are easier to apply precisely to the scalp without saturating adjacent hair, and they cause less scalp irritation than propylene-glycol-based solutions. FDA trial data shows 84.3% of men achieving stabilisation or measurable regrowth at 48 weeks of continued use.
Finasteride (Oral)
FDA-approved for male pattern hair loss in 1997 under the brand name Propecia, finasteride is a selective Type II 5-alpha reductase inhibitor. At the 1mg daily dose used for hair loss (as distinct from the 5mg dose used for benign prostatic hyperplasia), finasteride reduces serum DHT levels by approximately 70%. This suppression of DHT is the most direct pharmacological intervention available for androgenetic alopecia — it addresses the cause rather than a downstream effect.
The clinical evidence is substantial. In the pivotal 5-year trial, 87% of men taking finasteride showed no further hair loss at 2 years, and 66% showed measurable regrowth compared to their baseline. The placebo group continued to lose hair throughout. Finasteride requires a prescription in most jurisdictions. The safety profile is well-established over nearly three decades of use. Sexual dysfunction — including reduced libido, erectile dysfunction and ejaculatory disorders — is reported in approximately 2% of users in clinical trials. The post-finasteride syndrome (PFS), in which sexual side effects persist after cessation, is documented in the literature and is the subject of ongoing research; its incidence and mechanism remain subjects of scientific debate. Men considering finasteride should discuss this risk profile candidly with a prescribing physician.
Minoxidil + Finasteride Combined
Combination therapy consistently outperforms either monotherapy in head-to-head trials. A landmark 2019 study published in the Journal of the American Academy of Dermatology (JAAD) compared three arms over 24 weeks: the combination group showed a 24.7% increase in hair count; the minoxidil-only group showed 11.1%; the finasteride-only group showed 16.7%. The mechanistic logic is additive — finasteride addresses the hormonal driver while minoxidil independently extends the growth phase. For men in early-to-moderate androgenetic alopecia (Norwood II–IV) who have been evaluated by a dermatologist and have no contraindications, this combination represents the current evidence-based first-line approach.
Treatment Tier 2 — Emerging Evidence
Oral Minoxidil (Low-Dose)
Low-dose oral minoxidil — typically 0.25mg to 1.25mg daily — has emerged as a significant area of clinical interest since 2020. Multiple randomised controlled trials published between 2022 and 2024 demonstrate comparable efficacy to topical 5% minoxidil for vertex coverage, with significantly better treatment adherence (once-daily oral dosing versus twice-daily scalp application). The side-effect profile at these doses is distinct from the systemic effects seen at antihypertensive doses (150–300mg/day): the primary concerns are hypertrichosis (increased body hair, affecting approximately 25% of users) and mild dependent oedema. Oral minoxidil is prescribed off-label for hair loss in most markets; access and regulatory status vary by country.
Ketoconazole Shampoo (2%)
Ketoconazole is primarily an antifungal agent — and the gold-standard treatment for seborrhoeic dermatitis — but it also demonstrates mild anti-androgenic activity at the scalp level. It functions as a weak topical 5-alpha reductase inhibitor, reducing local DHT concentrations. A frequently cited 1998 study by Pierard-Franchimont et al. demonstrated comparable hair density improvements to 2% minoxidil when ketoconazole 2% shampoo was used 2–4 times weekly. The study has not been replicated at scale, and ketoconazole should not be considered a standalone treatment for androgenetic alopecia. However, the evidence is sufficient to recommend it as a complementary tool alongside minoxidil and/or finasteride — at essentially zero additional cost or side effect burden for most users.
PRP (Platelet-Rich Plasma)
PRP is a clinic-administered procedure in which the patient's own blood is drawn, centrifuged to concentrate platelets and growth factors, and injected directly into the scalp at sites of thinning. The rationale is that platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and other signalling proteins in the concentrated plasma stimulate dormant follicle activity and prolong the anagen phase. A 2019 meta-analysis covering 19 randomised controlled trials found statistically significant improvements in both hair count and hair shaft thickness. The evidence base is growing but remains heterogeneous — protocols differ between clinics, PRP preparation methods vary, and long-term data is limited. Cost ranges from $1,500 to $4,000 per initial course, with maintenance injections typically required every 6–12 months. PRP is most appropriate for men in early-stage androgenetic alopecia with still-viable, miniaturising follicles — not for advanced loss where follicles are fully inactive.
What Doesn't Work (Despite Marketing Claims)
Biotin supplementation is the most pervasive and probably the most profitable myth in hair loss marketing. Biotin (Vitamin B7) is a cofactor in keratin production — which is why its deficiency causes hair loss. But biotin deficiency is genuinely rare, affecting an estimated 1% of the general population. In the remaining 99% with normal biotin levels, supplementation produces no measurable effect on hair growth. Multiple dermatology society position statements, including from the American Academy of Dermatology, confirm this. Biotin supplements are harmless. They are not a hair loss treatment.
Saw palmetto is a natural 5-alpha reductase inhibitor that has attracted attention as a "natural alternative" to finasteride. Small studies have shown modest effects. Larger, well-controlled trials show primarily placebo-level responses. The inhibitory potency is orders of magnitude lower than finasteride, and the trials that show positive results tend to be small, poorly controlled, and frequently industry-funded.
DHT-blocking shampoos face a fundamental pharmacokinetic problem: to reduce DHT at the follicle level, an active compound needs sufficient dwell time on the scalp to achieve follicle penetration. Shampoo is rinsed off within 1–3 minutes. The therapeutic exposure window is insufficient. Ketoconazole at 2% is the partial exception — its antifungal mechanism operates differently — but it does not transform shampoo into a DHT blocker.
Low-level laser therapy (LLLT) devices — laser combs, laser caps — hold FDA clearance (Class III device clearance, not "approval"). The distinction is significant. Clearance requires demonstrating safety and substantial equivalence to an existing device, not clinical efficacy. The evidence base consists primarily of small, industry-sponsored trials with high placebo response rates and inconsistent outcome measures. Independent systematic reviews have not found sufficient evidence to recommend LLLT as a primary treatment for androgenetic alopecia.
The Realistic Timeline
Both topical minoxidil and finasteride require extended treatment periods before outcomes can be assessed. Topical minoxidil: the first 4–8 weeks often see a paradoxical increase in shedding — this is telogen effluvium, as dormant hairs are displaced by the advancing growing-phase hairs stimulated by minoxidil. This is a positive prognostic sign, not treatment failure. Initial response becomes visible at approximately 4 months; full response at 12 months. Finasteride: DHT suppression begins within days, but follicle recovery is a biological process measured in months. The 6-month mark is the earliest reliable assessment point; 12 months for maximum effect.
The most important variable: continuation. All pharmacological hair loss treatments are maintenance therapies. Stopping reverses gains within 3–6 months in the majority of patients, as DHT levels normalise (finasteride cessation) or the extended anagen effect ends (minoxidil cessation). This is not a failure of the treatment — it is the nature of treating a chronic, genetically driven condition with pharmaceutical tools.
Practical Starting Protocol — Evidence-Based
Step 1: Consult a dermatologist or trichologist. Confirm the diagnosis of androgenetic alopecia and rule out other causes — thyroid dysfunction, iron deficiency anaemia, zinc deficiency and telogen effluvium secondary to acute stress all present with hair loss and are treatable at the source.
Step 2: Begin topical 5% minoxidil foam. Apply to dry scalp twice daily (morning and evening). Do not use immediately before bed if scalp contact with the pillow is a concern — allow 4 hours for absorption. The foam formulation is preferred for its superior adherence and reduced scalp irritation compared to solution.
Step 3: Reassess at 6 months. If loss continues or the response to minoxidil is insufficient, discuss finasteride with your prescribing physician. The risk-benefit profile is well-documented. Make an informed decision in consultation with a clinician rather than based on internet forums.
Step 4: Add ketoconazole 2% shampoo 2–3 times weekly. No significant side-effect burden. Modest incremental benefit. Low cost.
"The evidence for minoxidil and finasteride is unambiguous. Everything else is filling the gap between clinical reality and consumer hope."
Male pattern hair loss is a legitimate medical condition with legitimate medical treatments. The industry surrounding it has evolved to obscure that simple fact — because the genuine treatments are relatively inexpensive and, in the case of finasteride, require a prescription that filters out impulse purchases. The consumer market fills the remainder with expensive noise. The protocol above is unglamorous, involves two drugs that have existed for decades, and costs less than most premium shampoos. That is precisely what the evidence looks like when the marketing is removed.
For more on scalp health and hair care fundamentals, see our hair category and the companion article Best Shampoo for Men 2026 — Ranked by Scalp Science.